Edgewise Therapeutics, Inc.

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

Edgewise Therapeutics reported new data from an ongoing Phase II trial of its cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy (HCM) on 2 April that it contends could improve upon t

Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by

Edgewise Therapeutics has unveiled impressive results from EDG-7500, a novel treatment for the heart condition, obstructive hypertrophic cardiomyopathy (oHCM), with early safety and efficacy data exc